Oryzon Genomics S.A (ORYZF PINK) stock market data APIs
$3.0529
0(0%)
as of May 12, 2025
Try our APIs with
free plan!
Oryzon Genomics S.A Financial Data Overview
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Prev. Close
3.0529
Open
3.0529
High
3.0529
Low
3.0529
52 wk Range
1.41-3.1
Market Cap
235 M
Shares Outstanding
77 477 K
Revenue
7 359 K
Beta
0.378
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oryzon Genomics S.A data using free add-ons & libraries
Get Oryzon Genomics S.A Fundamental Data
Oryzon Genomics S.A Fundamental data includes:
- Net Revenue: 7 359 K
- EBITDA: -4 376 387
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oryzon Genomics S.A News
New
Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder
Oryzon Genomics, S.A. Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in agitation and aggression and overall disease improvement Toplin...
ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023
Oryzon Genomics, S.A. Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical tri...
Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
Oryzon Genomics, S.A. Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patients PORTICO ...
ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
Oryzon Genomics, S.A. All resolutions were approved. 35% of the issued shares represented. MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
